AstraZeneca Opens $1 Billion R&D Center in Kendall Square
The company expands its Massachusetts workforce by over 50% while highlighting ivonescimab's potential for next-generation cancer treatments.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
First reported by Quartz, 1h 51m ahead of the next publisher · who breaks stories first
This story has stopped developing; this page is its permanent record. More from that day
The odds
Each tick is a source publishing on this story · 3 more published before price tracking began
Price data
| Time | Chance of yes |
|---|---|
| now | 47% |
| 7 Oct, 09:48 UTC | 47% |
| 6 Oct, 00:41 UTC | 55% |
Replay the odds, article by article
Step through each article in the order it published and watch a full approval or an accelerated approval respond.
The story so far
3 publishers have covered this in 6 articles since 5 Oct 2026. Quartz published first, on 5 October at 17:52 UTC; CNBC followed 1h 52m later. The most recent article, from STAT, appeared on 6 October at 14:41 UTC.
Outlets reporting it: CNBC (major outlet), Quartz, STAT.
One prediction market prices this story:
- a full approval or an accelerated approval — the market puts it at 47%, closing 1 Jan 2027. The market resolves to Yes if the FDA grants either a full or accelerated approval for Ivonescimab by Summit Therapeutics in 2026. It resolves to No if the FDA denies approval, requests more data, or takes no action within that year. Readers often mistake the linked news story about AstraZeneca’s new R&D center as relevant, but only the FDA's specific decision on this drug matters.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
How it unfolded
Every source in the order it published, with the odds on a full approval or an accelerated approval at that moment. A dash means the source published before we started tracking prices.
- QuartzAstraZeneca opens $1 billion R&D center in Kendall Square—
- QuartzAstraZeneca eröffnet ein 1 Milliarde Dollar teures F&E-Zentrum in Kendall Square.—
- CNBCAstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment—
- QuartzAstraZeneca CEO says Summit's cancer drug will drive next-gen combination treatments55%
- QuartzAstraZeneca-CEO sagt, dass Summit's Krebsmedikament nächste Generation von Kombinationsbehandlungen vorantreiben wird.55%
- STATSTAT+: AstraZeneca opens new Boston site55%
- Current odds47%
Sources
Every article we clustered into this story. Headlines link to the publisher.
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment CNBC ·
- STAT+: AstraZeneca opens new Boston site STAT
- AstraZeneca CEO says Summit's cancer drug will drive next-gen combination treatments Quartz
- AstraZeneca-CEO sagt, dass Summit's Krebsmedikament nächste Generation von Kombinationsbehandlungen vorantreiben wird. Quartz
- AstraZeneca eröffnet ein 1 Milliarde Dollar teures F&E-Zentrum in Kendall Square. Quartz
- AstraZeneca opens $1 billion R&D center in Kendall Square Quartz
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi a full approval or an accelerated approval 47%
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Email me when the odds move
In this story
- AstraZeneca
- Pascal Soriot
- Summit
- Kendall Square